CROSS-REFERENCE TO A RELATED APPLICATION

The present application claims priority based on U.S. Provisional Application No. 62/819,162, filed Mar. 15, 2019, which is incorporated herein by reference in its entirety.

BACKGROUND OF THE DISCLOSURE
1. Field of the Disclosure

The present disclosure relates to a method for treating pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) in a patient. The present disclosure further relates to a method for treating PAH/APAH via a systemic administration to a patient. The present disclosure yet further relates to a method for treating PAH/APAH in a patient with a single daily dose.

2. Description of the Prior Art

Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs. In PAH, increased pressure in the vessels is caused by obstruction in small arteries in the lungs and/or constriction or narrowing in diameter, which increases the resistance to blood flow through the lungs. Over time, the increased blood pressure can damage the heart. In many cases of pulmonary arterial hypertension, the cause is unknown. Others causes can be drug-related, HIV infection, and connective tissue/autoimmune disorders (such as scleroderma).

A type of PAH is associated pulmonary arterial hypertension (APAH). APAH can be PAH associated with other medical conditions including, for example, (1) collagen vascular disease (or connective tissue disease) which include autoimmune diseases such as scleroderma or lupus; (2) congenital heart and lung disease; (3) portal hypertension (e.g., resulting from liver disease); (4) HIV infection; (5) drugs (e.g., appetite suppressants, cocaine, and amphetamines; and (6) other conditions including thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, and splenectomy. APAH can also be PAH associated with abnormal narrowing in the pulmonary veins and/or capillaries such as in pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis.

Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that modulates central and peripheral functions by acting on neurons, smooth muscle, and other cell types. 5-HT is involved in the control and modulation of multiple physiological and psychological processes, including in lung and pulmonary diseases. The literature discloses the relationship between 5-HT and pulmonary diseases at PloS One 7, e31617 (2012), “The Role of Circulating Serotonin in the Development of Chronic Obstructive Pulmonary Disease” and Thorax 1999, 54, 161-168, “Role of Serotonin in the Pathogenesis of Acute and Chronic Pulmonary Hypertension”.

The rate-limiting step in 5-HT biosynthesis is the hydroxylation of tryptophan by dioxygen, which is catalyzed by tryptophan hydroxylase (TPH; EC 1.14.16.4) in the presence of the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). The resulting oxidized product, 5-hydroxy tryptophan (5-HTT) is subsequently decarboxylated by an aromatic amino acid decarboxylase (AAAD; EC 4.1.1.28) to produce 5-HT. Together with phenylalanine hydroxylase (PheOH) and tyrosine hydroxylase (TH), TPH belongs to the pterin-dependent aromatic amino acid hydroxylase family.

Two vertebrate isoforms of TPH, namely TPH1 and TPH2, have been identified. TPH1 is primarily expressed in the pineal gland and non-neuronal tissues, such as entei chromaffin (EC) cells located in the gastrointestinal (GI) tract. TPH2 (the dominant form in the brain) is expressed exclusively in neuronal cells, such as dorsal raphe or myenteric plexus cells. The peripheral and central systems involved in 5-HT biosynthesis are isolated, with 5-HT being unable to cross the blood-brain barrier. Therefore, the pharmacological effects of 5-HT can be modulated by agents affecting TPH in the periphery, mainly TPH1 in the gut.

WO 2015/035113 and U.S. Pat. No. 9,199,994 disclose spirocyclic compounds that act as inhibitors of THP and are useful in the treatment of various diseases and disorders associated with peripheral serotonin, including cardiovascular diseases of pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH).

However, there is a need for a method of treating or preventing PAH/APAH in a patient. There is a further need for a method of treating or preventing PAH/APAH in a patient with a systemic administration of a pharmaceutical compound or composition effective in modulating or ameliorating the effects of PAH/APAH. There is yet further need for a method of treating or preventing PAH/APAH in a patient with a pharmaceutical compound or composition containing a THP1 inhibitor.

SUMMARY OF THE DISCLOSURE

According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.

According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a composition including a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing, together with one or more pharmaceutically acceptable excipients. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.

According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a composition including a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing and a pharmaceutically acceptable excipient. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.

According to the present disclosure, there is provided the use of a therapeutically effective amount of a compound in treating PAH/APAH. The compound is selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof and (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.

According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing.

According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.

According to the present disclosure, there is provided a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing. The compound or pharmaceutically acceptable salt thereof is administered once per day.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present disclosure are described herein with reference to the following figures.

FIG. 1 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate according to the present disclosure (crystalline Form 3).

FIG. 2 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate of a different polymorphic form than that of FIG. 1 (crystalline Form 1).

DETAILED DESCRIPTION OF THE DISCLOSURE

Pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) is treated via administration of either or both of two spirocyclic compounds. Without being bound to any theory, each of the two spirocyclic compounds act to inhibit the formation of 5-HT, and, thus, diminish or ameliorate effects of PAH/APAH.

A useful spirocyclic compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate (also referred to herein as “RVT-1201”). The compound has the following formula:

[Image Omitted]

The above-referenced compound can be used to prevent or treat PAH/APAH in either an amorphous or crystalline form. Two different polymorph crystalline forms are identified by x-ray powder diffraction patterns set forth in FIG. 1 (Form 3) and FIG. 2 (Form 1) as well as Tables 1 and 2 (Form 3) and Tables 3 and 4 (Form 1). The crystalline Form 3 polymorph might be preferred, as it exhibits substantially greater stability and shelf life compared to the crystalline Form 1 polymorph, particularly at temperatures of less than 95° C.

TABLE 1

Observed Peaks for X-ray Powder Diffraction Pattern

for Compound RVT-1201, Crystalline Form 3

Peak position (°2θ)
d space (Å)
Intensity (%)

8.78 ± 0.20
10.077 ± 0.235
90

12.00 ± 0.20
7.375 ± 0.125
25

13.47 ± 0.20
6.573 ± 0.099
39

14.02 ± 0.20
6.316 ± 0.091
12

14.87 ± 0.20
5.956 ± 0.081
71

15.39 ± 0.20
5.757 ± 0.075
72

15.61 ± 0.20
5.677 ± 0.073
78

15.89 ± 0.20
5.576 ± 0.071
50

16.31 ± 0.20
5.434 ± 0.067
7

17.70 ± 0.20
5.011 ± 0.057
34

18.45 ± 0.20
4.809 ± 0.052
70

19.05 ± 0.20
4.658 ± 0.049
100

20.12 ± 0.20
4.413 ± 0.044
42

20.57 ± 0.20
4.317 ± 0.042
68

20.84 ± 0.20
4.262 ± 0.041
39

21.46 ± 0.20
4.141 ± 0.039
49

21.94 ± 0.20
4.051 ± 0.037
18

22.56 ± 0.20
3.941 ± 0.035
31

22.90 ± 0.20
3.884 ± 0.034
17

23.90 ± 0.20
3.723 ± 0.031
35

24.32 ± 0.20
3.660 ± 0.030
13

25.07 ± 0.20
3.552 ± 0.028
12

26.54 ± 0.20
3.359 ± 0.025
17

26.76 ± 0.20
3.332 ± 0.025
18

27.79 ± 0.20
3.210 ± 0.023
8

28.21 ± 0.20
3.163 ± 0.022
19

29.48 ± 0.20
3.030 ± 0.020
9

TABLE 2

Prominent Observed Peaks for X-ray Powder Diffraction Pattern

for Compound RVT-1201, Crystalline Form 3

Peak position

(°2θ)
d space (Å)
Intensity (%)

8.78 ± 0.20
10.077 ± 0.235
90

14.87 ± 0.20
5.956 ± 0.081
71

15.39 ± 0.20
5.757 ± 0.075
72

15.61 ± 0.20
5.677 ± 0.073
78

18.45 ± 0.20
4.809 ± 0.052
70

19.05 ± 0.20
4.658 ± 0.049
100

In yet another aspect, the Form 3 crystalline polymorph exhibits a characteristic XRPD peak at 19.05±0.20 (° 2θ).

The Form 1 crystalline compound exhibits the XRPD (X-ray powder diffraction) pattern set forth below in Table 3.

TABLE 3

Observed Peaks for X-Ray Powder Diffraction Pattern

for Compound RVT-1201, Crystalline Form 1

d space
Intensity

Peak position (°2θ)
(Å)
(%)

5.92 ± 0.20
14.936 ± 0.522
27

9.01 ± 0.20
9.816 ± 0.222
11

9.68 ± 0.20
9.140 ± 0.192
9

10.38 ± 0.20
8.523 ± 0.167
9

10.95 ± 0.20
8.082 ± 0.150
30

11.85 ± 0.20
7.468 ± 0.128
6

12.90 ± 0.20
6.861 ± 0.108
43

13.89 ± 0.20
6.376 ± 0.093
65

14.62 ± 0.20
6.057 ± 0.084
31

15.04 ± 0.20
5.890 ± 0.079
44

15.41 ± 0.20
5.750 ± 0.075
38

17.13 ± 0.20
5.176 ± 0.061
30

17.83 ± 0.20
4.974 ± 0.056
37

18.72 ± 0.20
4.741 ± 0.051
14

19.44 ± 0.20
4.567 ± 0.047
100

19.79 ± 0.20
4.487 ± 0.045
30

20.11 ± 0.20
4.417 ± 0.044
97

20.34 ± 0.20
4.366 ± 0.043
44

20.84 ± 0.20
4.262 ± 0.041
14

21.41 ± 0.20
4.151 ± 0.039
10

21.88 ± 0.20
4.063 ± 0.037
11

22.28 ± 0.20
3.991 ± 0.036
25

22.83 ± 0.20
3.895 ± 0.034
60

23.85 ± 0.20
3.731 ± 0.031
13

24.40 ± 0.20
3.648 ± 0.030
9

25.45 ± 0.20
3.500 ± 0.027
9

25.97 ± 0.20
3.431 ± 0.026
12

27.22 ± 0.20
3.276 ± 0.024
15

27.58 ± 0.20
3.235 ± 0.023
23

28.06 ± 0.20
3.180 ± 0.022
12

28.66 ± 0.20
3.115 ± 0.021
7

In still another aspect, the Form 1 crystalline compound exhibits prominent XRPD peaks set forth below in Table 4.

TABLE 4

Prominent Observed Peaks for X-Ray Powder Diffraction Pattern

for Compound RVT-1201, Crystalline Form 1

Peak position (°2θ)
d space (Å)
Intensity (%)

12.90 ± 0.20
6.861 ± 0.108
43

13.89 ± 0.20
6.376 ± 0.093
65

15.04 ± 0.20
5.890 ± 0.079
44

19.44 ± 0.20
4.567 ± 0.047
100

20.11 ± 0.20
4.417 ± 0.044
97

20.34 ± 0.20
4.366 ± 0.043
44

22.83 ± 0.20
3.895 ± 0.034
60

The amorphous form of the RVT-1201 compound can be prepared by the method set forth in Example 63i of U.S. Pat. No. 9,199,994 (corresponding to WO2015/054202), which is incorporated by reference herein in its entirety. The amorphous form can then be converted to crystalline form by extraction with organic solvents, such as C4 to C10 alcohols, C4 to C10 alkyl acetates, and ethers. Useful alcohols include pentane, hexane, and heptane. A useful ether is methyl tert butyl ether (MTBE). By way of example, crystalline form 1 can be prepared by extraction with isopropanol, ethanol, cyclohexane, ethyl acetate, acetone, water, and mixtures of the foregoing, while crystalline Form 3 can be prepared by extraction with MTBE and/or heptane. Crystalline Forms 1 and 3 can be prepared by the extraction techniques set forth in U.S. Provisional Application No. 62/767,171, filed Nov. 14, 2018, which is incorporated by reference herein in its entirety.

Another useful spirocyclic compound is (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]deca ne-3-carboxylic acid (herein alternately referred to as “KAR5417”) of the following formula:

[Image Omitted]

The amorphous form of the KAR5417 compound can be prepared by the method set forth in Example 34c of U.S. Pat. No. 9,199,994.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The efficacy of amorphous (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate in inhibiting TPH1 in mice was demonstrated in U.S. Pat. No. 9,199,994 in biological assays at Example 63i and Table 27.

As used herein, the term “patient” is used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and, most preferably, humans. Humans are inclusive of humans of any age, including adults and children, including infants.

As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

As used herein, the term “treating” or “treatment” refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).

As used herein, the term “preventing” or “prevention” refers to reducing risk incidence, delaying, or inhibiting the onset or worsening of the disease; for example, in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease, or an individual who has previously suffered from the disease, condition or disorder, but has been treated and, e.g., no longer displays the pathology or symptomatology of the disease.

The spirocyclic compounds can be administered to patients (animals or humans) in need of such treatment in appropriate dosages that will provide prophylactic and/or therapeutic efficacy. The dose required for use in the treatment or prevention of any particular disease or disorder will typically vary from patient to patient depending on, for example, particular compound or composition selected, the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors. The appropriate dosage can be determined by the treating physician; however, the dosage will be within the parameters defined herein.

The spirocyclic compounds can be administered systemically orally, subcutaneously, parenterally, by inhalation spray or rectally in dosage unit formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration can involve subcutaneous injections, intravenous or intramuscular injections or infusion techniques. Injectable liquids can include aqueous and/or organic components. Treatment duration can be as long as deemed necessary by a treating physician. The compositions can be administered as often as needed, e.g., one to four (or more) or more times per day. Administration can take place twice daily, thrice daily, daily, weekly, biweekly, twice weekly, every other week, monthly, and the like. A treatment period can terminate when a desired result, for example, a particular therapeutic effect, is achieved. However, in some instances, a treatment period can be continued indefinitely.

In some embodiments, pharmaceutical compositions can be prepared as solid dosage forms for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules and the like). Tablets can be prepared by compression and/or molding. Compressed tablets can include pharmaceutically acceptable excipients, such as, but not limited to, binders, lubricants, glidants, inert diluents, preservatives, disintegrants, and dispersing agents. Tablets and other solid dosage forms, such as, but not limited to, capsules, pills, powders, and granules, can include coatings, such as enteric coatings.

Liquid dosage forms for oral administration can include, for example, vehicles such as, but not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. The liquid vehicles can have aqueous and/or organic components. Suspensions can include one or more suspending agents. Examples of ingredients useful in liquid dosage forms include, but are not limited to, chelants, sequestering agents, viscosifiers, thickeners, penetration enhancers, solvents, emulsifiers, and emollients.

Pharmaceutical compositions suitable for parenteral administration can include the spirocyclic compound together with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions.

Alternatively, the composition can be in the form of a sterile powder that can be reconstituted into a sterile injectable solutions or dispersion just prior to use.

Solid and liquid dosage forms can be formulated such that they conform to a desired release profile, e.g., immediate release, delayed release, and extended or sustained release.

The amount of spirocyclic compound to be administered will vary depending on factors such as the following: the spirocyclic compound selected, method of administration, release profile, and composition formulation. Typically, for the two spirocyclic compounds, in an oral dosage form to treat or prevent PAH/APAH, a typical dosage will be about 1 mg/kg/day to about 50 mg/kg/day and more typically from about 5 mg/kg/day to about 30 mg/kg/day, based on the weight of the patient. A most preferred spirocyclic compound is RVT-1201 in crystalline Form 3. Individual oral dosage forms typically have from about 50 mg to about 3000 mg of a spirocyclic compound and additional amounts of one or more pharmaceutically acceptable excipients. Other useful individual oral dosage forms can, by way of example, have spirocyclic compound in amounts of 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg, 450 mg, 500 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, and about 1200 mg, particularly 1200 mg. A preferred dosage is 1200 mg. Other amounts between 50 mg to 3000 mg are possible, for example, from about 325 mg to about 475 mg, from about 350 mg to about 500 mg, from about 375 to about 525 mg, from about 400 mg to about 550 mg, from about 425 mg to about 575 mg, from about 450 mg to about 600 mg, from about 475 mg to about 625 mg, from about 500 mg to about 650 mg, from about 525 mg to about 675 mg, from about 550 mg to about 700 mg, from about 575 mg to about 725 mg, from about 600 mg to about 750 mg, from about 625 mg to about 775 mg, from about 650 mg to about 800 mg, from about 675 mg to about 825 mg, from about 700 mg to about 850 mg, from about 725 mg to about 875 mg, from about 750 mg to about 900 mg, from about 775 mg to about 925 mg, from about 800 mg to about 950 mg, from about 825 to about 975, from about 850 mg to about 1000 mg, from about 900 mg to about 1150 mg, from about 1000 mg to about 1150 mg, from about 1100 mg to about 1250 mg, and from about 1200 mg to about 1350 mg.

“wt %” means weight percent based on the total weight of the composition or formulation.

According to the present disclosure, there is also provided a method of treating or preventing PAH/APAH in a patient by administering to the patient a therapeutically effective amount of a THP1 inhibitor in the methods of administration and dosing levels described above. Further according to the present disclosure, there are also provided compositions, e.g., pharmaceutical compositions, useful for the treatment of PAH and/or APAH, and methods to treat PAH and/or APAH with such compositions. The compositions have one or more TPH1 inhibitors disclosed herein, and one or more pharmaceutically acceptable excipients.

The compositions of the present disclosure can comprise from about 10 mg to about 3000 mg of the one or more spirocyclic compounds disclosed herein, and one or more pharmaceutically acceptable excipients. The compositions of the present disclosure can comprise 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 600 mg, 610 mg, 620 mg, 630 mg, 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 670 mg, 680 mg, 690 mg, 700 mg, 710 mg, 720 mg, 730 mg, 740 mg, 750 mg, 760 mg, 770 mg, 780 mg, 790 mg, 800 mg, 810 mg, 820 mg, 830 mg, 840 mg, 850 mg, 860 mg, 870 mg, 880 mg, 890 mg, 900 mg, 910 mg, 920 mg, 930 mg, 940 mg, 950 mg, 960 mg, 970 mg, 980 mg, 990 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, and 1400 mg of the one or more spirocyclic compounds disclosed herein, and, additionally, one or more pharmaceutically acceptable excipients.

In another embodiment of the disclosure, compositions may have from about 10 mg to about 1400 mg of one or more TPH1 indicators disclosed herein, and one or more pharmaceutically acceptable excipients.

The spirocyclic compounds described above and pharmaceutically acceptable salts thereof are useful THP1 inhibitors. Other useful THP1 inhibitors include phenylalanine-derived TPH1 inhibitors, such as p-chlorophenylalanine and p-Ethynyl phenylalanine. See “p-Ethynylphenylalanine: A Potent Inhibitor Of Tryptophan Hydroxylase”, Journal of Neurochemistry 74, 2067-73 (2000). Other useful THP1 inhibitors include substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids. See “A Tryptophan 5-hydroxylase Inhibitor, And Its Potential In Chronic Diarrhea Associated With Increased Serotonin”, Neurogastroenterology and Motility: The Official Journal of The European Gastrointestinal Motility Society 23, 193-200 (2011); “Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic Acids As Novel Tryptophan Hydroxylase Inhibitors” Bioorganic & Medicinal Chemistry Letters 19, 5229-32 (2009); “Modulation Of Peripheral Serotonin Levels By Novel Tryptophan Hydroxylase Inhibitors For The Potential Treatment Of Functional Gastrointestinal Disorders” Journal of Medicinal Chemistry 51, 3684-7 (2008); and “Discovery And Characterization of Novel Tryptophan Hydroxylase Inhibitors that Selectively Inhibit Serotonin Synthesis in the Gastrointestinal Tract”, The Journal of Pharmacology and Experimental Therapeutics, 325, 47-55 (2008)).

The embodiments of the present disclosure are also useful in treating any form or category of pulmonary hypertension (PH) in general. PAH and APAH are forms of PH, with APAH also being a form of PAH. Other forms of PAH include idiopathic pulmonary arterial hypertension (IPAH) and heritable pulmonary arterial hypertension (HPAH). IPAH is a form of PAH that arises without any apparent origin or cause. HPAH is a form of PAH that arises due to mutations in PAH predisposing genes or from hereditary origin

The following are examples of the disclosure and are not to be construed as limiting.

EXAMPLES
Example 1

In rat, orally administered RVT-1201 at a dose of 100 mg/kg/day (KAR5417 AUC_0-24ng·h/mL) may block or ameliorate PAH in both a monocrotaline prevention model and a SUGEN-hypoxia treatment model for established PAH. RVT-1201 (30 to 300 mg/kg/day) may yield a dose-dependent reduction in rat serum serotonin (−27% to −96%) and 24 h urinary output of 5-HIAA (−45% to −56%). HIAA is a metabolite that reflects total serotonin biosynthesis.

Divided dose studies in rats given 75 mg/kg/day (˜65% serotonin reduction) may demonstrate KAR5417 AUC_0-24, rather than C_maxor C_trough, correlated with lowered serotonin biomarkers. Once daily administration to rats may show it is comparable to BID or TID regimens.

Example 2

Healthy human subjects (n=˜120) may receive RVT-1201. Of treatment emergent adverse events received, none will be serious, nor considered a dose limiting toxicity. With standard meals, AUC following single doses will appear proportional to dose of 200 to −1200 mg).

At 400 mg BID (twice daily), changes in 5-HIAA will be comparable across studies. Mean change in plasma 5-HIAA may be about −53% from Day 1 to Day 14, whereas placebo may be about +26%. Interpolation of KAR5417 AUC between 400 mg and 800 mg BID regimens may show 500-600 mg BID in humans will achieve the target exposure associated with efficacy in rat models. In summary, RVT-1201 may be well tolerated in healthy subjects at doses required to achieve clinically-relevant AUC, and lowering of serotonin biomarkers for treatment of PAH.

Example 3
Purpose

TPH1 is the rate-limiting enzyme for peripheral biosynthesis of serotonin (5HT), which has been implicated as a causative factor in PAH. RVT-1201 decreased pulmonary vessel wall thickness in 2 PAH rodent models indicating potential to halt/reverse pulmonary remodeling in humans. The median effective dose (100 mg/kg QD) in PAH rat models yielded a ˜35% reduction in 5-HT biosynthesis (based on urinary 5-HIAA, a metabolite of 5HT). Divided-dose pharmacodynamic (PD) studies in healthy rats (QD vs BID vs TID) demonstrated KAR5417 AUC, rather than Cmax or Cmin, best correlated with lowering of 5-HT, indicating QD dosing (once daily) was as effective as more frequent dosing. The example compares reductions in 5-HIAA levels following QD and BID dosing in healthy subjects.

Methods

24 healthy subjects received 800 mg total daily oral doses of RVT-1201 or placebo (PBO), either as single (800 mg QD) or divided (400 mg BID) doses for 14 days across two cohorts (9 active: 3 PBO per cohort). KAR5417 plasma levels and change from Baseline (BSL) PD biomarker data (plasma and urine 5-HIAA) were compared between QD and BID cohorts at day 14. Safety and tolerability were assessed via adverse event (AE) monitoring and laboratory, vital signs and ECG assessments.

Results

At day 14, KAR5417 mean (±SD) AUC_0-24at 800 mg QD (9180 ng*h/mL, ±4280) was comparable to the mean pAUC_0-24for 400 mg BID (10400 ng*h/mL, ±3260). 5-HT lowering was similar across both dose regimens, with 800 mg QD achieving mean (±SD) 40.0 (6.32) % and (6.59) % reductions in plasma and urinary 5-HIAA at day 14, respectively, compared to 49.9 (9.52) % and 55.5 (10.3) % reductions, respectively, with the 400 mg BID regimen. Plasma and urinary 5-HIAA levels were largely unchanged from BSL in the PBO arms. 5-HIAA reductions in both regimens exceeded those associated with efficacy in the rodent models. Both dose regimens were generally well-tolerated. The overall incidence of GI-related AEs was greater in the QD group (78%) compared to the divided dose group (33%). However, most AEs were mild in intensity and there were no treatment-related withdrawals in either cohort.

CONCLUSIONS

Once daily oral dosing of RVT-1201 achieved reductions in serotonin biosynthesis comparable to those associated with reversal of vascular remodeling in PAH animal models. Repeated QD dosing of RVT-1201 reduced 5-HT biosynthesis similarly to divided (BID) daily dosing. Reductions in 5-HIAA levels were comparable to those associated with reversal of vascular remodeling in animal PAH models. RVT-1201 was generally well-tolerated in both dose regimens.

Clinical Implications

RVT-1201 has the potential to reduce serotonin production and impact vascular remodeling in PAH patients. If ultimately proven effective, the potential to dose RVT-1201 once-daily may help improve overall treatment adherence in a disease like PAH in which patients often take more than one drug in combination chronically.

It should be understood that the foregoing description is only illustrative of the present disclosure. Various alternatives and modifications can be devised by those skilled in the art without departing from the present disclosure. Accordingly, the present disclosure is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims.